Key result
Aspirin-free strategies utilizing P2Y12 inhibitor monotherapy after a short course of DAPT represent a promising approach to reduce bleeding risk in selected patients with acute coronary syndromes.
Why the study?
Do aspirin-free strategies improve outcomes in patients with acute coronary syndromes treated with percutaneous coronary intervention?
Do aspirin-free strategies improve outcomes in patients with acute coronary syndromes treated with percutaneous coronary intervention?
This overview discusses the future of aspirin-free antiplatelet strategies in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Spadafora et al. (2022) conducted a letter in Acute coronary syndromes (ACS) treated with percutaneous coronary intervention (PCI). Aspirin-free strategies (P2Y12 inhibitor monotherapy) vs. Standard dual antiplatelet therapy (DAPT) was evaluated. Aspirin-free strategies utilizing P2Y12 inhibitor monotherapy after a short course of DAPT represent a promising approach to reduce bleeding risk in selected patients with acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: